Interactive modules by Olga Goodman, MD.Copyright protected · Read termsClose terms

All RheumaView™ interactive modules, quizzes and educational cases are original works developed by Olga Goodman, MD.

Without the author’s prior written permission, you may not copy or republish these modules or their components; extract, reuse or modify their original software code (“engines”); or use that code to build your own modules, quizzes or other products.

You may not claim these works as your own or remove or replace the author’s name or copyright notices. When quoting material, credit Olga Goodman, MD, identify the source and include a direct link to the original.

Free or public access is provided for learning and does not grant permission to copy, adapt or redistribute the materials. Unauthorized use of protected material may constitute copyright infringement. Exceptions and limitations provided by applicable law remain unaffected.

Sharing direct links to the modules is welcome.

© 2026 Olga Goodman, MD. All rights reserved.

Professional collection · English

Stem Cells & Perinatal Therapies · Professional series · EN

Stem Cells & Perinatal Therapies

Very promising science. Product-specific evidence. A higher standard of clinical judgment.

By Olga Goodman, MD · Evidence through 25 September 2026

From immune-directed research to tissue repair, cell-based medicine opens important possibilities. The question is which defined product may help which clinical problem, on what evidence, and under what conditions.

SELECT YOUR QUESTION

Choose a clinical route

Follow the indication, then compare product identity, study design and the outcome that matters.

FOR PATIENTS & FAMILIES

Keep the promise. Ask better questions.

A complete guide to the proposed product, the applicable evidence, the limits and the questions to bring to an independent consultation.

ORIENT THE EVIDENCE

Begin with the fundamentals

Four short routes into the core questions behind a responsible clinical recommendation.

PROFESSIONAL COLLECTION · EN

Explore every article

Browse by theme or search for a condition, product or clinical question.

01

Foundations

  1. Stem cells: why the promise deserves precision

    An optimistic introduction without treating a diverse scientific field as a single treatment.

  2. HSCs, MSCs, BMAC, SVF: a vocabulary that changes decisions

    The labels on a brochure are not enough to identify the biological intervention.

  3. Umbilical cord and placental therapies: the source is not the treatment

    Cord blood, Wharton’s jelly, placental membranes, and extracts need separate evidence pathways.

  4. Immunomodulation and repair: what might the cells actually do?

    Why a sophisticated mechanism is a starting point, not the final clinical answer.

  5. The next frontier: what could make cell therapy genuinely transformative

    An author’s research agenda for turning biological promise into reproducible clinical value.

02

Rheumatology

  1. Hematopoietic transplantation in rheumatology: a different level of intervention

    Selected systemic sclerosis care must not be confused with retail regenerative infusions.

  2. MSC therapy in rheumatoid arthritis: promising research, not a shortcut around diagnosis

    Interpret early biological signals and long-term follow-up without confusing inflammation, damage, and pain.

  3. Lupus and lupus nephritis: a strong rationale needs controlled clinical answers

    What early trials and the 2026 real-world report can—and cannot—tell a person with refractory disease.

  4. Beyond RA and lupus: Sjögren’s, psoriasis, and other autoimmune disease

    Keep the immune hypothesis open without transporting an indication from one disease to another.

03

Musculoskeletal repair

  1. Osteoarthritis and cartilage: symptom relief is not the same as regeneration

    Positive small studies, a larger randomized trial, and the importance of the structural endpoint.

  2. Tendons, ligaments, spine, and rehabilitation: match the target to the intervention

    A framework for evaluating regenerative proposals outside the main arthritis trials.

04

Functional medicine & aging

  1. Functional medicine, frailty, and longevity: define what “better” means

    New human research is worth attention without turning selected frailty findings into universal rejuvenation.

  2. Placental extracts: a separate subject within perinatal medicine

    How to discuss a biologically complex preparation without mislabeling it as living-cell therapy.

05

Aesthetic medicine

  1. Cell-based and perinatal approaches in aesthetic medicine

    Keep skin biology, visible outcomes, tissue repair, and systemic disease in the same clinical conversation.

06

Clinical judgment

  1. Product quality: the science hidden behind the vial

    Identity, viability, potency, release testing, and traceability are part of the treatment—not administrative extras.

  2. Approval, authorization, registration: words that are not interchangeable

    A United States–focused framework with a dated European example.

  3. Safety, uncertainty, and follow-up: compare the right risks

    Neither “natural” nor “experimental” is a complete risk assessment.

  4. Why the quality of the recommendation matters as much as the procedure

    A high-level consultation integrates disease expertise, cell biology, evidence appraisal, and responsibility for the outcome.

07

Related—but separate

  1. PRP and exosomes: related ideas, separate therapies

    A boundary chapter, not a substitute for their own indication-specific evidence reviews.

08

Evidence & practical review

  1. The evidence desk: important findings through September 25, 2026

    A dated, selective review of primary studies and official regulatory records—not an exhaustive systematic review.

  2. Before you decide: the independent consultation planner

    A printable way to organize a proposal without turning a checklist into medical clearance.

RELATED FIELDS · DISTINCT EVIDENCE

Keep the therapies separate.

PRP and extracellular vesicles/exosomes require their own product- and indication-specific assessment. CAR-T is engineered immune-cell therapy.

Olga Goodman, MD · Rheumatology in Perspective · A RheumaView publication

Educational publication; not individualized medical advice or procedure clearance. No dosing protocol is provided. This is a selective, dated review rather than an exhaustive systematic review.

Original text requires author and source attribution. Do not submit personal medical information in public comments.

Back to top

Share this page

FacebookLinkedInXWhatsAppTelegram

Topics: cell therapyperinatal therapiesregenerative medicinestem cells